Medicine and Dentistry
Liver Graft
100%
Alcohol Liver Disease
83%
Malignant Neoplasm
76%
Hepatocellular Carcinoma
55%
Antibiotic Therapy
41%
Alcohol Liver Cirrhosis
41%
Adenosine Triphosphate
41%
Mitochondrion
41%
Granulocyte Colony Stimulating Factor
41%
Immunotherapy
41%
Underserved Population
41%
Tuberculous Peritonitis
41%
Liver Injury
41%
Transplantation
41%
Hepatitis A
41%
Kidney Injury
41%
Roux-en-Y Gastric Bypass
41%
Peritoneum
41%
Nivolumab
41%
Allograft
41%
Chronic Hepatitis C
41%
Programmed Cell Death
34%
Reactive Oxygen Species
31%
Immune Checkpoint Inhibitor
29%
Liver Transplantation
27%
Injury
27%
Antiviral Therapy
27%
Acute Graft Rejection
27%
Hepatitis C Virus
25%
Patient Population
24%
Mitochondrial Permeability
20%
Mycobacterium Tuberculosis
20%
Reperfusion Injury
20%
Oxidative Stress
20%
Necrosis
20%
Liver Disease
20%
Mortality Rate
16%
Alcoholic Polyneuropathy
16%
Biopsy
13%
Virus Resistance
13%
Graft Failure
13%
Toxic Hepatitis
13%
Fibrosis
13%
Antivirus Agent
13%
Drug Therapy
13%
Patient Monitoring
13%
Overall Survival
11%
Disease
11%
Clinical Trial
11%
Mitochondrial Permeability Transition Pore
10%
Keyphrases
SS-31
41%
Advanced Hepatocellular Carcinoma
41%
Peritoneum
41%
Risk Factors
41%
Underserved Populations
41%
Roux-en-Y Gastric Bypass
41%
Diverse Populations
41%
Peritoneal Tuberculosis
41%
Tuberculosis
41%
Chronic Hepatitis C
41%
Immune Checkpoint Inhibitors
41%
Hepatocellular Cancer
41%
Immunotherapy Efficacy
41%
Cirrhotic Patients
41%
Direct-acting
41%
Antibiotic Therapy
41%
United States
41%
Metabolic Risk Factors
41%
Metabolic Obesity
41%
Liver Transplant Recipients
41%
Metabolic Dysfunction
41%
Metabolic Health
41%
Patient Demographics
34%
Direct-acting Antiviral Therapy
27%
Hepatitis C Virus
22%
Child-Pugh
22%
Susceptibility Profile
20%
Intermittent Fever
20%
Mycobacterium Tuberculosis (M. tb)
20%
Tuberculosis Risk
20%
Developed Countries
20%
Abdominal Distension
20%
Fever
20%
Ascitic Fluid
20%
Elevated Liver Tests
20%
Post-liver Transplant
20%
Liver Transplant Evaluation
20%
Preoperative Risk Assessment
20%
Anatomical Constraints
20%
Strict Control
20%
Alcohol Use Disorder
20%
Complications of Liver Transplantation
20%
Bariatric Surgery
20%
Liver Disease
20%
Immunosuppressive Therapy
20%
Sarcopenic Obesity
20%
Growing Patients
20%
Operative
20%
Liver Failure
20%
Metabolic-associated Fatty Liver Disease (MAFLD)
20%
Pharmacology, Toxicology and Pharmaceutical Science
Alcohol Liver Disease
83%
Alcohol Liver Cirrhosis
41%
Malignant Neoplasm
41%
Adenosine Triphosphate
41%
Granulocyte Colony Stimulating Factor
41%
Kidney Injury
41%
Hepatitis A
41%
Liver Cell Carcinoma
41%
Immunotherapy
41%
Reactive Oxygen Metabolite
31%
Inflammation
31%
Immune Checkpoint Inhibitor
26%
Necrosis
20%
Reperfusion Injury
20%
Mortality Rate
16%
Overall Survival
10%
Ischemia
10%
Mitochondrial Permeability Transition Pore
10%
Disease
10%
Tetrapeptide
10%
Clinical Trial
10%
Hepatitis C Virus
10%
Acute Kidney Failure
10%
Tubular Dysfunction
10%
Rat Model
10%
End Stage Liver Disease
9%
Infection
9%
Ethanol
9%
Retrospective Study
8%